Skip to main content
Mayinglong Pharmaceutical Group Co.,Ltd logo

Mayinglong Pharmaceutical Group Co.,Ltd — Investor Relations & Filings

Ticker · 600993 ISIN · CNE000001HN2 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 931 across all filing types
Latest filing 2026-05-08 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 600993

About Mayinglong Pharmaceutical Group Co.,Ltd

https://www.mayinglong.cn/

Mayinglong Pharmaceutical Group Co.,Ltd. is a long-established enterprise specializing in the research, development, and production of Traditional Chinese Medicine (TCM). Founded in 1582, the company is widely recognized for its expertise in proctology, maintaining a dominant market position with its signature hemorrhoid ointments and suppositories. Its product portfolio also includes ophthalmic preparations, dermatological treatments, and gastrointestinal medicines. The company integrates traditional medicinal formulas with modern manufacturing technologies to provide healthcare solutions. Beyond pharmaceuticals, Mayinglong has expanded into healthcare services, including specialized hospitals and personal care products, focusing on the integration of clinical treatment and health management.

Recent filings

Filing Released Lang Actions
马应龙关于控股子公司终止转让下属控股公司股权的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the termination of a share transfer transaction by a controlling subsidiary of the company. It details the background of the transaction, the failure of the counterparty to fulfill payment obligations, and the consequent termination of the transaction. There is no financial report, audit, or detailed financial data presented. The document is a regulatory announcement about a capital transaction that was terminated, not a report or detailed financial statement. This fits best under Capital/Financing Update (CAP) as it relates to a financing/capital transaction update.
2026-05-08 Chinese
马应龙2025年内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2025年度内部控制评价报告' which translates to '2025 Internal Control Evaluation Report'. It is a detailed report on the company's internal control effectiveness as of December 31, 2025. The content includes evaluation conclusions, scope, standards for defect recognition, and remediation status. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 3909 characters, which is relatively short but contains substantive evaluation content rather than just an announcement or certification. The nature of the report aligns with an Audit Report / Information (AR) category, as it deals with internal control evaluation and audit opinions on internal controls, which is typical for audit-related standalone reports. It is not an Annual Report (10-K) or Interim Report (IR) because it does not cover full financial performance or quarterly results. It is not a Regulatory Filing (RNS) because it contains substantive evaluation content, not just a certification or announcement. Therefore, the best classification is AR (Audit Report / Information).
2026-04-24 Chinese
马应龙2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "马应龙药业集团股份有限公司2026年第一季度报告" which translates to "Mayinglong Pharmaceutical Group Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and shareholder information for the first quarter of 2026. The report explicitly states it is a quarterly report and includes unaudited financial statements for the period ending March 31, 2026. The length of the document (15,000 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR).
2026-04-24 Chinese
马应龙关于为子公司提供担保额度的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by the company 马应龙药业集团股份有限公司 regarding the provision of guarantee limits for its subsidiaries. It details the guarantee amounts, the subsidiaries involved, internal decision procedures, risk assessments, and board approval. The content focuses on the company's guarantee commitments to its subsidiaries, including financial data related to these guarantees and risk disclosures. There is no indication that this is a full financial report, audit report, or earnings release. It is not a call transcript, nor a management or investor presentation. The document is a regulatory announcement about financing-related guarantees, which fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and capital commitments. The document length is 4460 characters, which is consistent with an announcement rather than a full report. Therefore, the classification is CAP with high confidence.
2026-04-24 Chinese
马应龙2025年度独立董事述职报告（梅之南）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Annual Report" for the year 2025 by an independent director of the company. It details the director's duties, attendance at board and shareholder meetings, communication with auditors, and oversight activities during the year. It does not contain financial statements or detailed financial data but rather a narrative report on the director's activities and compliance with governance rules. This type of document is a management or board-related report focusing on governance and director duties rather than a full annual report or audit report. It is not a certification or a short announcement but a substantive report on director activities. Therefore, the best fitting category is Board/Management Information (MANG). The document length (2844 characters) and content support this classification with high confidence.
2026-04-24 Chinese
马应龙董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a special opinion from the board regarding the independence of the company's independent directors, referencing regulatory guidelines from the China Securities Regulatory Commission and the Shanghai Stock Exchange. It assesses the independence of specific directors and confirms compliance with relevant rules. The document is short (436 characters) and focuses on governance and board matters rather than financial results or reports. It does not contain financial data or detailed management discussion. Therefore, it fits best under Board/Management Information (MANG), which covers announcements about board or senior management matters.
2026-04-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.